Y0000522
炔诺酮
European Pharmacopoeia (EP) Reference Standard
同義詞:
17α-乙炔基-19-去甲睾酮, 17-羟基-19-去甲-17α-孕甾-4-烯-20-炔基-3-酮, 17α-乙炔基-17β-羟基-19-去甲-4-雄甾烯-3-酮, 19-去甲-17α-乙炔基-4-雄甾烯-17β-醇-3-酮, 去甲基脱氢羟孕酮
登入查看組織和合約定價
全部照片(1)
About This Item
經驗公式（希爾表示法）:
C20H26O2
CAS號碼:
分子量：:
298.42
Beilstein:
1915671
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24
推薦產品
等級
pharmaceutical primary standard
API 家族
norethisterone
製造商／商標名
EDQM
mp
205-206 °C (lit.)
應用
pharmaceutical (small molecule)
格式
neat
儲存溫度
−20°C
SMILES 字串
[H][C@]12CCC(=O)C=C1CC[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@@]4(O)C#C
InChI
1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,15-18,22H,4-11H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1
InChI 密鑰
VIKNJXKGJWUCNN-XGXHKTLJSA-N
基因資訊
human ... PGR(5241)
尋找類似的產品？ 前往 產品比較指南
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Norethisterone for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生化／生理作用
炔诺酮是用于抑制细胞溶质磺基转移酶类 (SULT) 的口服避孕药。
包裝
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他說明
Sales restrictions may apply.
相關產品
產品號碼
描述
訂價
訊號詞
Danger
危險分類
Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 2 - Lact. - Repr. 1A
儲存類別代碼
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
水污染物質分類（WGK）
WGK 3
Chelsea B Polis et al.
The Lancet. Infectious diseases, 13(9), 797-808 (2013-07-23)
Whether or not the use of hormonal contraception affects risk of HIV acquisition is an important question for public health. We did a systematic review, searching PubMed and Embase, aiming to explore the possibility of an association between various forms
Derin J Cobia et al.
Schizophrenia research, 139(1-3), 1-6 (2012-06-01)
Cortical abnormalities are considered a neurobiological characteristic of schizophrenia. However, the pattern of such deficits as they progress over the illness remains poorly understood. The goal of this project was to assess the progression of cortical thinning in frontal and
Patricia M LoRusso et al.
Cancer chemotherapy and pharmacology, 71(1), 193-202 (2012-10-16)
Vismodegib, a first-in-class oral hedgehog pathway inhibitor, is an effective treatment for advanced basal cell carcinoma. Based on in vitro data, a clinical drug-drug interaction (DDI) assessment of cytochrome P450 (CYP) 2C8 was necessary; vismodegib's teratogenic potential warranted a DDI
Karl van den Broeck et al.
The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception, 17(5), 321-328 (2012-09-15)
Ferdinand Peeters, a practising gynaecologist from Turnhout, near Antwerp (Belgium), had a pivotal role in the development of a practical and viable modality of oral contraception, striking the balance between efficacy and an acceptably low incidence and severity of side
Kelli Stidham Hall et al.
Contraception, 86(6), 653-658 (2012-06-12)
Progestin-only contraceptive pills (POPs) offer a safe and effective contraceptive option, particularly for women at increased risk of venous thromboembolism. However, the prevalence of POP use among women in the United States is unknown. We analyzed population-based data from 12,279
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務